MVX ONCO 1

Drug Profile

MVX ONCO 1

Alternative Names: MaxiVax vaccine; MVX-1 loaded autologous tumour vaccine; MVX-1-loaded macrocapsule/autologous tumour cell vaccine - MaxiVax; MVX-ONCO1

Latest Information Update: 23 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MaxiVax
  • Class Cancer vaccines; Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Head and neck cancer

Most Recent Events

  • 27 Jun 2017 Phase-II clinical trials in Head and neck cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease) in Switzerland (SC) (NCT02999646) (MaxiVax website, August 2017)
  • 07 Oct 2016 Final adverse events data from a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therpy) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 09 Feb 2016 MaxiVax completes a phase I trial in Solid tumours in Switzerland (MaxiVax website; February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top